This study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid plaque density as measured by histopathological assessment. The study will address the following specific aims: 1. To expand the number of subjects included in the A07 (NCT00857415) trial correlation analysis (measuring the correlation between the global visual rating of brain amyloid plaque density on an independent blinded read of the florbetapir F 18 PET scan and the cortical amyloid plaque density at autopsy as assessed by histopathology for subjects in the autopsy cohort). 2. To determine the sensitivity and specificity of an independent blinded visual read assessment of the florbetapir F 18 PET scan (Aβ+ or Aβ-) versus the final blinded neuropathological assessment made at autopsy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Sensitivity Analysis in All Autopsy Population
Timeframe: at autopsy within 24 months of florbetapir PET scan
Specificity Analysis in All Autopsy Population
Timeframe: at autopsy within 24 months of florbetapir PET scan
Correlation of Florbetapir-PET Image and Amyloid Plaque Density
Timeframe: at autopsy within 24 months of florbetapir PET scan